Genetic Markers for Focal Segmental Glomerulosclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001393 |
Recruitment Status
:
Recruiting
First Posted
: November 4, 1999
Last Update Posted
: April 2, 2018
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date | November 3, 1999 | ||||||||
First Posted Date | November 4, 1999 | ||||||||
Last Update Posted Date | April 2, 2018 | ||||||||
Study Start Date | April 19, 1994 | ||||||||
Primary Completion Date | Not Provided | ||||||||
Current Primary Outcome Measures |
To develop a molecular understanding of racial differences in the incidence of podocyte diseases. [ Time Frame: Ongoing ] | ||||||||
Original Primary Outcome Measures | Not Provided | ||||||||
Change History | Complete list of historical versions of study NCT00001393 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures | Not Provided | ||||||||
Original Secondary Outcome Measures | Not Provided | ||||||||
Current Other Outcome Measures | Not Provided | ||||||||
Original Other Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title | Genetic Markers for Focal Segmental Glomerulosclerosis | ||||||||
Official Title | Genetic Markers for Focal Segmental Glomerulosclerosis | ||||||||
Brief Summary | Glomerulonephritis is a disease which affect the kidneys. Occasionally these diseases can progress to a loss of kidney function in some patients. Glomerulosclerosis or focal segmental glomerulosclerosis (FSGS) is one form of glomerulonephritis. The cause of FSGS is unknown and often occurs on its own (idiopathic), or it can be associated with HIV (Human Immunodeficiency Virus). FSGS occurs more commonly among black patients than Caucasian or Hispanic patients. Researchers believe that environmental factors may interact with genetic mutations to cause FSGS, at least in some patients. This study will attempt to identify genetic factors associated with the development of FSGS. The study population will be made up of 600 total subjects divided into 3 groups. Group one will be 200 African-Americans with FSGS. Group two will be 200 African-Americans with HIV but without FSGS. Group three will be 200 non-African-Americans with FSGS. Study participation requires that researchers obtain 20 ml (2 tubes of blood). The genetic material (DNA) will be prepared from the white blood cells and analyzed. The results of each group will be compared with the results from the other groups to determine if one or more genes predisposes to FSGS. In the long run, studies that demonstrate a genetic basis for FSGS may help us identify patients earlier and may lead to improved therapies. |
||||||||
Detailed Description | Focal segmental glomerulosclerosis (FSGS) and a related condition, collapsing glomerulopathy, are chronic renal diseases affecting the glomerular podocytes. Currently, over thirteen genetic mutations are associated with FSGS. We are interested in expanding our understanding of these and other genes that may cause FSGS and collapsing glomerulopathy. We will study individuals with affected family members. We will also study sporadic cases; the rationale for studying this population is that FSGS and collapsing glomerulopathy are significantly more common among individuals of African descent. The latter observation suggests that particular FSGS-susceptibility alleles may be more common among African Americans. In the present study, we are addressing the hypothesis that genetic variation contributes to the pathogenesis of idiopathic FSGS and collapsing glomerulopathy, both idiopathic and HIV associated variants. We are studying the following groups:
We are taking three methodologic approaches. First, we are examining known FSGS risk genes or candidate genes, looking for disease-causing mutations and for disease-susceptibility haplotypes. Second, we have undertaken a genome scan, in the African descent population. We may also undertake a whole genome scan in European and Asian descent. Evidence of linkage disequilibrium among these markers will be sought between patients with and without FSGS. Third, when we identify families with multiple affected individuals and which lack known genetic mutations affecting FSGS genes, we will pursue positional cloning. |
||||||||
Study Type | Observational | ||||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||||||
Target Follow-Up Duration | Not Provided | ||||||||
Biospecimen | Not Provided | ||||||||
Sampling Method | Not Provided | ||||||||
Study Population | Not Provided | ||||||||
Condition |
|
||||||||
Intervention | Not Provided | ||||||||
Study Groups/Cohorts | Not Provided | ||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status | Recruiting | ||||||||
Estimated Enrollment |
99999999 | ||||||||
Original Enrollment |
9999 | ||||||||
Study Completion Date | Not Provided | ||||||||
Primary Completion Date | Not Provided | ||||||||
Eligibility Criteria |
|
||||||||
Sex/Gender |
|
||||||||
Ages | 19 Months and older (Child, Adult, Senior) | ||||||||
Accepts Healthy Volunteers | Yes | ||||||||
Contacts |
|
||||||||
Listed Location Countries | United States | ||||||||
Removed Location Countries | Canada, Israel | ||||||||
Administrative Information | |||||||||
NCT Number | NCT00001393 | ||||||||
Other Study ID Numbers | 940133 94-DK-0133 |
||||||||
Has Data Monitoring Committee | Not Provided | ||||||||
U.S. FDA-regulated Product | Not Provided | ||||||||
IPD Sharing Statement | Not Provided | ||||||||
Responsible Party | National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ) | ||||||||
Study Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||||||||
Collaborators | Not Provided | ||||||||
Investigators |
|
||||||||
PRS Account | National Institutes of Health Clinical Center (CC) | ||||||||
Verification Date | January 24, 2018 |